GMP IPO Watch
PGIM India Healthcare Fund
Direct Plan · Direct IDCW · PGIM India Mutual Fund
Returns
Annualised (CAGR) returns for periods over a year.
Want to invest in this fund?
Open a free demat & trading account with Zerodha to invest in direct mutual funds with zero commission.
Rank in Category
| Period | This Fund | Category Avg. | Rank |
|---|---|---|---|
| 1W | +3.17% | +3.52% | 191 of 255 |
| 1M | +0.90% | +1.97% | 192 of 255 |
| 3M | +0.08% | -3.45% | 34 of 252 |
| 6M | +15.96% | +2.92% | 13 of 251 |
| YTD | +23.50% | +1.21% | 6 of 255 |
| 1Y | +20.03% | +1.11% | 7 of 232 |
| INCEPTION | +11.89% | — | — |
Ranked among: Equity Scheme - Sectoral/ Thematic.
Rolling Returns
| Period | Average | Best | Worst | Positive Periods | Consistency |
|---|---|---|---|---|---|
| 3M | +4.34% | +21.90% | -12.40% | 71% | 29% |
| 6M | +8.71% | +30.21% | -8.54% | 80% | 34% |
| 1Y | +13.21% | +29.31% | -2.97% | 91% | 40% |
Rolling returns show the average, best and worst outcome an investor would have seen entering at any point in the window.
NAV History
AUM Trend (₹ Cr, quarterly average)
Expense Ratio Trend
Portfolio · Sep 2026
Asset Allocation
- Equity94.89%
- Debt0.00%
- Cash5.11%
- Other0.00%
Market Cap Split
- Large Cap31.14%
- Mid Cap35.32%
- Small Cap28.43%
- Others5.11%
Fundamentals
| Fund | Category | |
|---|---|---|
| P/E | 46.06 | 41.75 |
| P/B | 8.33 | 6.19 |
| Price / Sales | 8.04 | 5.96 |
| Price / Cash Flow | 35.78 | 30.98 |
| Dividend Yield (%) | 0.58 | 0.61 |
Holdings · Sep 2026
| Holding | Sector | Weight | Change (1M) |
|---|---|---|---|
| Divis Laboratories | Pharmaceuticals & Biotechnology | 10.36% | -0.49% |
| Sun Pharmaceutical | Pharmaceuticals & Biotechnology | 10.25% | -0.49% |
| Torrent Pharmaceuticals | Pharmaceuticals & Biotechnology | 8.49% | -0.37% |
| Clearing Corporation of India Ltd. | Net Current Assets | 5.24% | — |
| Ajanta Pharma | Pharmaceuticals & Biotechnology | 4.96% | +0.13% |
| Max Healthcare Institute | Equity | 4.71% | -0.25% |
| Dr. Lal Path Labs | Equity | 4.33% | +0.40% |
| Mankind Pharma | Pharmaceuticals & Biotechnology | 4.04% | -0.03% |
| Manipal Health Enterprises | Equity | 3.68% | -0.44% |
| Navin Fluorine International | Chemicals & Petrochemicals | 3.24% | +0.20% |
| Abbott | Pharmaceuticals & Biotechnology | 3.12% | +0.29% |
| Krishna Institute of Medical Sciences | Equity | 2.99% | -0.16% |
| Rubicon Research | Pharmaceuticals & Biotechnology | 2.99% | -1.02% |
| Neuland Laboratories | Pharmaceuticals & Biotechnology | 2.91% | -0.35% |
| Aster DM Quality Care | Equity | 2.56% | -0.33% |
View all 33 holdings
| Sai Life Sciences | Pharmaceuticals & Biotechnology | 2.54% | +0.00% |
| ICICI Lombard General Insurance | Insurance | 2.10% | +0.70% |
| Cipla | Pharmaceuticals & Biotechnology | 2.04% | -0.19% |
| Zydus Life Science | Pharmaceuticals & Biotechnology | 2.04% | +0.53% |
| Lupin | Pharmaceuticals & Biotechnology | 1.93% | +0.51% |
| IPCA Laboratories | Pharmaceuticals & Biotechnology | 1.92% | +1.41% |
| Dr. Agrawals Eye Hospital | Equity | 1.86% | +0.66% |
| Anthem Biosciences | Pharmaceuticals & Biotechnology | 1.81% | -0.15% |
| Global Health | Equity | 1.52% | -0.20% |
| Gland Pharma | Pharmaceuticals & Biotechnology | 1.50% | +0.77% |
| Jupiter Life Line Hospital | Equity | 1.46% | -0.31% |
| Fortis Healthcare | Equity | 1.46% | +0.36% |
| Symbiotec Pharmalab | Pharmaceuticals & Biotechnology | 1.10% | — |
| Lenskart Solutions | Retailing | 0.99% | +0.28% |
| Molbio Diagnostics | Equity | 0.80% | — |
| Orchid Pharma | Pharmaceuticals & Biotechnology | 0.79% | -0.01% |
| Sagility | IT - Services | 0.40% | -0.06% |
| Net Receivables / (Payables) | Net Current Assets | -0.13% | — |
Sector Allocation · Sep 2026
Risk Metrics
Standard Deviation
| Period | Fund | Category | |
|---|---|---|---|
| 1Y | 12.80 | 16.32 | Low Volatility |
What is this?
Annualized population standard deviation of daily denomination-adjusted NAV returns, multiplied by sqrt(252). Values require a full timeframe of NAV history.
Sharpe Ratio
| Period | Fund | Category | |
|---|---|---|---|
| 1Y | 0.82 | -0.32 | Above Average |
| 3Y | 0.34 | -0.45 | Above Average |
What is this?
Annualized Sharpe ratio calculated from month-end NAV returns using the latest available FBIL Overnight MIBOR rate as the risk-free rate. For schemes with less than three years of history, the 3Y value uses since-inception data. Applied risk-free rate: 5.73% (published 2026-10-28).
Sortino Ratio
| Period | Fund | Category | |
|---|---|---|---|
| 1Y | 2.30 | 0.19 | Above Average |
What is this?
Annualized from daily NAV returns using a 0.00% minimum acceptable return; downside deviation includes only returns below this target.
Beta
| Period | Fund | Category | |
|---|---|---|---|
| 1Y | 1.06 | 0.96 | Poor Risk Adjusted Returns |
What is this?
This value gives idea about how volatile fund performance has been compared to similar funds in the market. Lower beta implies the fund gives more predictable performance compared to similar funds in the market.
Compare With Peers
| Scheme | 1Y | 3Y | 5Y | Since Inception |
|---|---|---|---|---|
|
Nippon India Taiwan Equity Fund
Regular Plan · IDCW option
|
+59.64% | +47.37% | — | +23.17% |
|
HDFC Pharma and Healthcare Fund
Direct Plan · IDCW Option
|
+25.51% | +31.04% | — | +30.18% |
|
Kotak Healthcare Fund
Regular Plan · IDCW Option
|
+23.57% | — | — | +20.10% |
|
SBI Automotive Opportunities Fund
Direct Plan · IDCW
|
+22.37% | — | — | +11.34% |
|
Mirae Asset Healthcare Fund
Direct Plan · Growth
|
+21.28% | +24.36% | +16.89% | +22.00% |
|
ICICI Prudential US Bluechip Equity Fund
Regular Plan · IDCW
|
+20.32% | +18.33% | +12.09% | +15.77% |
|
Nippon India Japan Equity Fund
Regular Plan · Bonus Option
|
+18.89% | +19.86% | +8.28% | +8.45% |
|
HDFC Defence Fund
Regular Plan · IDCW Option
|
+18.80% | +34.56% | — | +36.67% |
|
HSBC India Export Opportunities Fund
Direct Plan · Growth
|
+18.74% | — | — | +9.24% |
|
SBI HEALTHCARE OPPORTUNITIES FUND
Regular Plan · IDCW
|
+18.71% | +23.84% | +18.25% | +12.20% |
More From PGIM India Asset Management Private Limite
| Scheme | 1Y | 3Y | 5Y | Since Inception |
|---|---|---|---|---|
|
PGIM India Global Select Real Estate Securities Fund of Fund
Direct Plan · Direct Growth
|
+13.32% | +14.96% | — | +4.97% |
|
PGIM India Small Cap Fund
Direct Plan · Direct Growth
|
+9.52% | +15.36% | +11.72% | +13.35% |
|
PGIM India Arbitrage Fund
Direct plan · Growth
|
+6.56% | +7.03% | +6.51% | +6.11% |
|
PGIM India Liquid Fund
Direct Plan · Direct Growth
|
+6.53% | +6.94% | +6.46% | +6.26% |
|
PGIM India Money Market Fund
Direct Plan · Direct Growth
|
+6.20% | +7.11% | +6.66% | +6.12% |
|
PGIM India Ultra Short Term Fund
Direct Plan · Direct Growth
|
+6.16% | +7.00% | +6.52% | +7.30% |
|
PGIM India Multi Cap Fund
Direct Plan · Direct IDCW
|
+6.04% | — | — | +3.63% |
|
PGIM India Overnight Fund
Direct Plan · Direct Growth
|
+5.14% | +5.95% | +5.74% | +5.11% |
|
PGIM India CRISIL IBX Gilt Index - Apr 2028 Fund
Direct Plan · Direct Growth
|
+4.44% | +7.10% | — | +7.24% |
|
PGIM India Emerging Markets Equity Fund of Fund
Direct Plan · Direct Growth
|
+3.76% | +19.57% | +0.81% | +6.04% |
About This Scheme
Investment Objective
The primary investment objective of the scheme is to seek to generate consistent returns by predominantly investing in equity and equity related securities of pharmaceutical and healthcare companies. However, there is no assurance that the investment objective of the scheme will be achieved. The Scheme does not guarantee/ indicate any returns.
Stated Asset Allocation
Equity and equity related securities of pharmaceutical and healthcare companies- Min 80% and Max 100% Equity & Equity Related Securities of other companies- Min 0% and Max 20% Money Market Instruments and, other liquid instruments, Units of Liquid, Money Market and Overnight Mutual funds - Min 0% and Max 20% Units issued by InvITs - Min 0% and Max 10% Foreign securities including overseas ETFs - Min 0% and Max 20% Units of Gold ETFs & Silver ETFs - Min 0% and Max 20%
Exit Load
For Exits within 90 days from date of allotment of units: 0.50%; For Exits beyond 90 days from date of allotment of units: NIL.
Fund Managers
Mr. Anandha Padmanabhan Anjeneyan, Mr. Utsav Mehta, Mr. Vivek Sharma and Mr. Puneet Pal
Description - Asset classwise we have different Fund Manager. Anandha Padmanabhan Anjeneyan is a Primary Fund Manager for Equity, Utsav Mehta is a Comanage Fund Manager for Equity, Vivek Sharma is a Comanage Fund Manager for Equity and Puneet Pal for Debt.
Mutual fund investments are subject to market risks. Read all scheme related documents carefully. Past performance is not indicative of future returns. Data is sourced from AMFI and fund houses via FinAPI and may lag official figures.